Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Serum Amyloid A Is Associated with Obesity and Estrogen Receptor-Negative Tumors in Postmenopausal Women with Breast Cancer

Texto completo
Autor(es):
Santana, Aline Barros [1] ; Costa Gurgel, Maria Salete [2, 3] ; de Oliveira Montanari, Joelma Ferreira [3] ; Bonini, Flavia Muraro [1] ; de Barros-Mazon, Silvia [1]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] State Univ Campinas UNICAMP, Fac Med Sci, Dept Clin Pathol, Campinas, SP - Brazil
[2] State Univ Campinas Unicamp, Fac Med Sci, Dept Obstet & Gynecol, Campinas, SP - Brazil
[3] State Univ Campinas Unicamp, Fac Med Sci, Ctr Integral Attent Womens Hlth CAISM, Campinas, SP - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION; v. 22, n. 2, p. 270-274, FEB 2013.
Citações Web of Science: 3
Resumo

Serum amyloid A (SAA) is an acute-phase protein and also an adipokine, which has been associated with the development and prognosis of breast cancer. In the present study, we investigated the association between obesity and SAA in postmenopausal women with breast cancer and its relationship with clinicopathologic characteristics of tumors. Patients were grouped as nonobese or overweight/obese based on body mass index (BMI) plus waist circumference measurement. Serum SAA concentrations were determined by high-sensitivity micro-latex agglutination tests, detected by nephelometry. Serum SAA concentrations were higher in overweight/obese (P = 0.008) patients and this condition was dependent on obesity (BMI and waist circumference), as further shown by multivariate linear regression analysis done for SAA (P = 0.01). Concentrations of SAA were also higher in patients with estrogen receptor-negative (ER-) tumors than in those with estrogen receptor-positive (ER+; P = 0.033). Our results suggest a possible role for SAA in the development and prognosis of obesity-related breast cancer. A follow-up study of this population to assess overall and disease-free survival is in course and should bring contribution to evaluate the clinical role of SAA in breast cancer in the context of obesity. Cancer Epidemiol Biomarkers Prev; 22(2); 270-4. (c) 2013 AACR. (AU)

Processo FAPESP: 09/17084-7 - Soro amilóide A e adiponectina: caracterização no câncer de mama na pós-menopausa e relação com obesidade
Beneficiário:Sílvia de Barros Mazon
Modalidade de apoio: Auxílio à Pesquisa - Regular